

Sun Pharma's Aggrenox gets USFDA nod

24 August 2018 | News | By Sonali Wankhade

This is a generic copy of Boehringer Ingelheim Pharma's drug Aggrenox (Aspirin/Dipyridamole). Aggrenox and its generics are estimated to have US sales of ~\$230mn in the US



Sun Pharma has received final USFDA approval for Aspirin and Dipyridamole. This is a generic copy of Boehringer Ingelheim Pharma's drug Aggrenox.

Aggrenox is used to lower the risk of stroke in people who have had a mini-stroke or stroke due to a blood clot.

Aggrenox and its generics are estimated to have US sales of approximately \$230mn in the US and with the lower competition, Sun pharma expect to make \$8-10mn/annum from this drug.